** Shares of Traws Pharma TRAW.O fall 17.2% to $1.06 premarket

** Co late on Friday said it has delayed a mid-stage human trial of its influenza drug after the UK medicines regulator gave it a negative review

** The tivoxavir marboxil drug's planned human challenge study, which was reviewed by UK's Medicines and Healthcare Products Regulatory Agency (MHRA), has been deferred

** TRAW said it is advancing backup drug candidates that match the original drug's long-acting profile and antiviral strength, but without any mutagenic potential

** In February, the U.S. FDA placed on clinical hold its investigational new drug application for tivoxavir marboxil, due to "concerns with the mutagenicity data package"

** Co has cash runway extending to Q1 2027

** As of last close, stock up 13.4% YTD